SPRO - Spero Therapeutics, Inc.
IEX Last Trade
0.93
0.000 -0.011%
Share volume: 1,326
Last Updated: Thu 26 Dec 2024 04:14:35 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$0.93
0.00
-0.01%
Fundamental analysis
22%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
15%
Performance
5 Days
-1.84%
1 Month
-18.48%
3 Months
-26.76%
6 Months
-29.51%
1 Year
-30.56%
2 Year
-39.52%
Key data
Stock price
$0.93
DAY RANGE
$0.93 - $0.94
52 WEEK RANGE
$0.95 - $1.89
52 WEEK CHANGE
-$33.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Ankit A. Mahadevia
Region: US
Website: sperotherapeutics.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sperotherapeutics.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Spero Therapeutics, Inc. focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
Recent news